Versameb

About Versameb

Versameb AG, a privately held biopharmaceutical company, is focused on the discovery and development of therapeutic RNA-based drugs. Headquartered in Basel, Switzerland, the company was established in 2017. The firm was co-founded by Professor Dr. Friedrich Müllhaupt, who also serves as the Chairman of the Board of Directors, and Dr. Klaas Zuideveld, who holds the position of Chief Executive Officer. Dr. Zuideveld brings over two decades of experience in the pharmaceutical and biotech sectors, with a background that includes roles at Roche and as CEO of an oncology-focused biotech company. This experience in drug development and corporate leadership is central to Versameb's strategic direction. The company's scientific foundation is built upon its proprietary VERSagile platform.

The VERSagile platform is the core of Versameb's operations, designed to engineer RNA molecules with tailored therapeutic properties. This technology enables the company to create molecules that can enhance protein expression, with the potential to simultaneously target multiple proteins or address specific cell types. This capability allows for the development of drug candidates intended to regenerate tissues and treat a range of diseases. Versameb's primary focus is on addressing indications in dermatology and myology, with a lead candidate, VMB-100, developed for the treatment of Stress Urinary Incontinence (SUI). The business model revolves around advancing its pipeline candidates through preclinical and clinical development stages. The ultimate goal is to partner with larger pharmaceutical companies for late-stage development and commercialization, or to bring products to market independently. The company's revenue generation is tied to achieving development milestones, securing licensing agreements, and future product sales.

Financially, Versameb has secured funding through several financing rounds, indicating investor confidence in its technology and pipeline. Notable financing events include a CHF 6.4 million seed and Series A round in 2021 and a CHF 5.5 million Series A extension in 2022. These funds are primarily allocated to advancing the VMB-100 program into clinical trials and further developing the VERSagile platform. The company operates within the competitive biotechnology market, specifically in the RNA therapeutics space, targeting areas with significant unmet medical needs. Its strategy is to leverage the unique capabilities of its platform to create first-in-class therapies for hard-to-treat diseases.